Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 378

1.

The role of ADAMTS-13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study.

Obermeier HL, Riedl J, Ay C, Koder S, Quehenberger P, Bartsch R, Kaider A, Zielinski CC, Pabinger I.

Res Pract Thromb Haemost. 2019 May 6;3(3):503-514. doi: 10.1002/rth2.12197. eCollection 2019 Jul.

PMID:
31294335
Free PMC Article
2.

Validated Assessment Scales for Skin Laxity on the Posterior Thighs, Buttocks, Anterior Thighs, and Knees in Female Patients.

Kaminer MS, Casabona G, Peeters W, Bartsch R, Butterwick K, Yen-Yu Chao Y, Costa J, Eviatar J, Fabi SG, Geister TL, Goldie K, Grice J, Hexsel D, Lorenc P, Lupo M, Pooth R, Sattler G, Waldorf HA, Yutskovskaya Y, Kerscher M.

Dermatol Surg. 2019 Jun 24. doi: 10.1097/DSS.0000000000001994. [Epub ahead of print]

PMID:
31246868
3.

Validated Assessment Scales for Cellulite Dimples on the Buttocks and Thighs in Female Patients.

Hexsel D, Fabi SG, Sattler G, Bartsch R, Butterwick K, Casabona G, Yen-Yu Chao Y, Costa J, Eviatar J, Geister TL, Goldie K, Grice J, Kerscher M, Lorenc P, Lupo M, Peeters W, Pooth R, Waldorf HA, Yutskovskaya Y, Kaminer MS.

Dermatol Surg. 2019 Jun 24. doi: 10.1097/DSS.0000000000001993. [Epub ahead of print]

PMID:
31246867
4.

Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial.

Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M, Singer C, Bartsch R, Schrenk P, Soelkner L, Greil R, Gnant M; ABCSG.

Ann Surg. 2019 Jun;269(6):1163-1169. doi: 10.1097/SLA.0000000000002771.

PMID:
31082916
5.

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F; International Breast Cancer Study Group and the Breast International Group.

Lancet Oncol. 2019 Mar;20(3):371-382. doi: 10.1016/S1470-2045(18)30812-X. Epub 2019 Feb 11.

PMID:
30765258
6.

Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases.

Bergen ES, Berghoff AS, Medjedovic M, Rudas M, Fitzal F, Bago-Horvath Z, Dieckmann K, Mader RM, Exner R, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Clin Cancer Res. 2019 May 1;25(9):2737-2744. doi: 10.1158/1078-0432.CCR-18-1968. Epub 2019 Jan 15.

PMID:
30647078
7.

ASCO 2018: highlights in HER2-positive metastatic breast cancer.

Bartsch R, Bergen E.

Memo. 2018;11(4):280-283. doi: 10.1007/s12254-018-0441-x. Epub 2018 Oct 11. Review.

8.

Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center.

Füreder LM, Widhalm G, Gatterbauer B, Dieckmann K, Hainfellner JA, Bartsch R, Zielinski CC, Preusser M, Berghoff AS.

Clin Exp Metastasis. 2018 Dec;35(8):727-738. doi: 10.1007/s10585-018-9947-1. Epub 2018 Nov 12.

9.

Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).

Rinnerthaler G, Gampenrieder SP, Petzer A, Burgstaller S, Fuchs D, Rossmann D, Balic M, Egle D, Rumpold H, Singer CF, Bartsch R, Petru E, Melchardt T, Ulmer H, Mlineritsch B, Greil R.

BMC Cancer. 2018 Nov 6;18(1):1074. doi: 10.1186/s12885-018-4979-0.

10.

Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.

Tahmassebi A, Wengert GJ, Helbich TH, Bago-Horvath Z, Alaei S, Bartsch R, Dubsky P, Baltzer P, Clauser P, Kapetas P, Morris EA, Meyer-Baese A, Pinker K.

Invest Radiol. 2019 Feb;54(2):110-117. doi: 10.1097/RLI.0000000000000518.

PMID:
30358693
11.

SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy.

Bartsch R, Bergen E.

Memo. 2018;11(3):204-207. doi: 10.1007/s12254-018-0430-0. Epub 2018 Aug 17. Review.

12.

Current concepts and future directions in neoadjuvant chemotherapy of breast cancer.

Bartsch R, Bergen E, Galid A.

Memo. 2018;11(3):199-203. doi: 10.1007/s12254-018-0421-1. Epub 2018 Jul 19. Review.

13.

CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion.

Preusser M, De Mattos-Arruda L, Thill M, Criscitiello C, Bartsch R, Ruhstaller T, de Azambuja E, Zielinski CC.

ESMO Open. 2018 Aug 20;3(5):e000368. doi: 10.1136/esmoopen-2018-000368. eCollection 2018. Review. Erratum in: ESMO Open. 2019 Mar 11;4(2):e000368corr1.

14.

Human relevance of follicular thyroid tumors in rodents caused by non-genotoxic substances.

Bartsch R, Brinkmann B, Jahnke G, Laube B, Lohmann R, Michaelsen S, Neumann I, Greim H.

Regul Toxicol Pharmacol. 2018 Oct;98:199-208. doi: 10.1016/j.yrtph.2018.07.025. Epub 2018 Aug 1. Review.

PMID:
30076866
15.

Performance-based approach for movement artifact removal from electroencephalographic data recorded during locomotion.

Arad E, Bartsch RP, Kantelhardt JW, Plotnik M.

PLoS One. 2018 May 16;13(5):e0197153. doi: 10.1371/journal.pone.0197153. eCollection 2018.

16.

Neuronal noise as an origin of sleep arousals and its role in sudden infant death syndrome.

Dvir H, Elbaz I, Havlin S, Appelbaum L, Ivanov PC, Bartsch RP.

Sci Adv. 2018 Apr 25;4(4):eaar6277. doi: 10.1126/sciadv.aar6277. eCollection 2018 Apr.

17.

Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial.

Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M, Singer C, Bartsch R, Schrenk P, Soelkner L, Greil R, Gnant M; ABCSG.

Ann Surg. 2018 Apr 24. doi: 10.1097/SLA.0000000000002771. [Epub ahead of print]

PMID:
29697452
18.

ESMO 2017-my personal highlights.

Kiesewetter B, Dediu M, Bartsch R.

Memo. 2018;11(1):77-79. doi: 10.1007/s12254-018-0385-1. Epub 2018 Feb 16.

19.

My burning issues in the neoadjuvant treatment for breast cancer.

Bergen ES, Bartsch R.

Memo. 2018;11(1):27-30. doi: 10.1007/s12254-017-0378-5. Epub 2017 Dec 22. Review.

20.

Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients.

Kowalczyk L, Bartsch R, Singer CF, Farr A.

Breast Care (Basel). 2017 Dec;12(6):401-408. doi: 10.1159/000480492. Epub 2017 Dec 3. Review.

21.

Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non-Small Cell Lung Cancer.

Hashim M, Pfeiffer BM, Bartsch R, Postma M, Heeg B.

Value Health. 2018 Jan;21(1):9-17. doi: 10.1016/j.jval.2017.07.011. Epub 2017 Sep 6. Review.

22.

Ribociclib: a valuable addition to treatment options in breast cancer?

Bartsch R.

ESMO Open. 2017 Aug 23;2(3):e000246. doi: 10.1136/esmoopen-2017-000246. eCollection 2017. No abstract available.

23.

ASCO 2017: highlights in breast cancer.

Bartsch R, Bergen E.

Memo. 2017;10(4):228-232. doi: 10.1007/s12254-017-0368-7. Epub 2017 Nov 13. Review.

24.

Biosimilars in the Treatment of Breast Cancer.

Balic M, Bartsch R, Bauernhofer T, Vrbanec D, Vrdoljak E.

Breast Care (Basel). 2017 Jul;12(3):192-194. doi: 10.1159/000477926. Epub 2017 Jun 13. No abstract available.

25.

Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: A retrospective analysis of 624 patients.

Masel EK, Berghoff AS, Füreder LM, Heicappell P, Schlieter F, Widhalm G, Gatterbauer B, Dieckmann U, Birner P, Bartsch R, Schur S, Watzke HH, Zielinski CC, Preusser M.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12707. Epub 2017 May 10.

PMID:
28488812
26.

My personal highlights of ESMO 2016.

Dediu M, Gerger A, Zojer N, Bartsch R.

Memo. 2017;10(1):46-47. doi: 10.1007/s12254-017-0314-8. Epub 2017 Feb 8.

27.

Quantifying cardio-respiratory phase synchronization-a comparison of five methods using ECGs of post-infarction patients.

Kuhnhold A, Schumann AY, Bartsch RP, Ubrich R, Barthel P, Schmidt G, Kantelhardt JW.

Physiol Meas. 2017 May;38(5):925-939. doi: 10.1088/1361-6579/aa5dd3. Epub 2017 Feb 2.

PMID:
28151433
28.

Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.

Singer CF, Tan YY, Fitzal F, Steger GG, Egle D, Reiner A, Rudas M, Moinfar F, Gruber C, Petru E, Bartsch R, Tendl KA, Fuchs D, Seifert M, Exner R, Balic M, Bago-Horvath Z, Filipits M, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2017 Jul 15;23(14):3676-3683. doi: 10.1158/1078-0432.CCR-16-2373. Epub 2017 Jan 31.

29.

Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score.

Berghoff AS, Wolpert F, Holland-Letz T, Koller R, Widhalm G, Gatterbauer B, Dieckmann K, Birner P, Bartsch R, Zielinski CC, Weller M, Preusser M.

Neuro Oncol. 2017 Sep 1;19(9):1255-1262. doi: 10.1093/neuonc/now290.

30.

Extravasation emergencies: state-of-the-art management and progress in clinical research.

Pluschnig U, Haslik W, Bartsch R, Mader RM.

Memo. 2016;9(4):226-230. doi: 10.1007/s12254-016-0304-2. Epub 2016 Dec 5. Review.

31.

ASCO 2016: highlights in breast cancer.

Bartsch R, Bergen E.

Memo. 2016;9(4):211-214. doi: 10.1007/s12254-016-0300-6. Epub 2016 Nov 30. Review.

32.

Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases.

Furtner J, Berghoff AS, Albtoush OM, Woitek R, Asenbaum U, Prayer D, Widhalm G, Gatterbauer B, Dieckmann K, Birner P, Aretin B, Bartsch R, Zielinski CC, Schöpf V, Preusser M.

Eur Radiol. 2017 Aug;27(8):3167-3173. doi: 10.1007/s00330-016-4707-6. Epub 2017 Jan 3.

33.

I-SPY 2: optimising cancer drug development in the 21st century.

Bartsch R, de Azambuja E.

ESMO Open. 2016 Nov 15;1(5):e000113. eCollection 2016. No abstract available.

34.

The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna.

Kiesewetter B, Raderer M, Steger GG, Bartsch R, Pirker R, Zöchbauer-Müller S, Prager G, Krainer M, Preusser M, Schmidinger M, Zielinski CC.

ESMO Open. 2016 Jul 4;1(4):e000066. eCollection 2016.

35.

Recent developments and translational aspects in targeted therapy for metastatic breast cancer.

Marhold M, Bartsch R, Zielinski C.

ESMO Open. 2016 May 4;1(3):e000036. eCollection 2016. Review.

36.

Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers.

Berghoff AS, Schur S, Füreder LM, Gatterbauer B, Dieckmann K, Widhalm G, Hainfellner J, Zielinski CC, Birner P, Bartsch R, Preusser M.

ESMO Open. 2016 Mar 16;1(2):e000024. eCollection 2016.

37.

Modulations of Heart Rate, ECG, and Cardio-Respiratory Coupling Observed in Polysomnography.

Penzel T, Kantelhardt JW, Bartsch RP, Riedl M, Kraemer JF, Wessel N, Garcia C, Glos M, Fietze I, Schöbel C.

Front Physiol. 2016 Oct 25;7:460. eCollection 2016. Review.

38.

Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).

Berghoff AS, Ricken G, Wilhelm D, Rajky O, Widhalm G, Dieckmann K, Birner P, Bartsch R, Preusser M.

J Neurooncol. 2016 Oct;130(1):19-29. Epub 2016 Jul 19.

PMID:
27436101
39.

Focus on the emerging new fields of Network Physiology and Network Medicine.

Ivanov PC, Liu KKL, Bartsch RP.

New J Phys. 2016 Oct;18. pii: 100201. doi: 10.1088/1367-2630/18/10/100201.

40.

Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer.

Minarikova L, Bogner W, Pinker K, Valkovič L, Zaric O, Bago-Horvath Z, Bartsch R, Helbich TH, Trattnig S, Gruber S.

Eur Radiol. 2017 May;27(5):1901-1911. doi: 10.1007/s00330-016-4565-2. Epub 2016 Sep 20.

41.

Diffusion-weighted MRI of breast lesions: a prospective clinical investigation of the quantitative imaging biomarker characteristics of reproducibility, repeatability, and diagnostic accuracy.

Spick C, Bickel H, Pinker K, Bernathova M, Kapetas P, Woitek R, Clauser P, Polanec SH, Rudas M, Bartsch R, Helbich TH, Baltzer PA.

NMR Biomed. 2016 Oct;29(10):1445-53. doi: 10.1002/nbm.3596. Epub 2016 Aug 24.

PMID:
27553252
42.

Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy.

Exner R, Sachet M, Arnold T, Zinn-Zinnenburg M, Michlmayr A, Dubsky P, Bartsch R, Steger G, Gnant M, Bergmann M, Bachleitner-Hofmann T, Oehler R.

Cancer Med. 2016 Sep;5(9):2350-8. doi: 10.1002/cam4.827. Epub 2016 Jul 25.

43.

Pathological complete remission and long-term outcome-what do we know in 2016?

Gnant M, Steger GG, Bartsch R.

Lancet Oncol. 2016 Jun;17(6):693-694. doi: 10.1016/S1470-2045(16)30038-9. Epub 2016 May 11. No abstract available.

PMID:
27179401
44.

Prognostic impact of breast cancer subtypes in elderly patients.

Bergen ES, Tichy C, Berghoff AS, Rudas M, Dubsky P, Bago-Horvath Z, Mader RM, Exner R, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Breast Cancer Res Treat. 2016 May;157(1):91-9. doi: 10.1007/s10549-016-3787-y. Epub 2016 Apr 23.

45.

Delay-correlation landscape reveals characteristic time delays of brain rhythms and heart interactions.

Lin A, Liu KK, Bartsch RP, Ivanov PCh.

Philos Trans A Math Phys Eng Sci. 2016 May 13;374(2067). pii: 20150182. doi: 10.1098/rsta.2015.0182.

46.

A Cross-Sectional Study of Patients' Satisfaction With Totally Implanted Access Ports.

Minichsdorfer C, Füreder T, Mähr B, Berghoff AS, Heynar H, Dressler A, Gnant M, Zielinski C, Bartsch R.

Clin J Oncol Nurs. 2016 Apr;20(2):175-80. doi: 10.1188/16.CJON.175-180.

PMID:
26991711
47.

Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.

Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, Bilocq A, Heinzl H, Zielinski C, Bartsch R, Birner P, Galon J, Preusser M.

Oncoimmunology. 2015 Jun 9;5(1):e1057388. eCollection 2016.

48.

Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.

Thallinger C, Lang I, Kuhar CG, Bartsch R, Singer CF, Petruzelka L, Melichar B, Knittelfelder R, Brodowicz T, Zielinski C.

BMC Cancer. 2016 Feb 18;16:121. doi: 10.1186/s12885-016-2171-y.

49.

Palbociclib for the treatment of postmenopausal breast cancer - an update.

Steger GG, Gnant M, Bartsch R.

Expert Opin Pharmacother. 2016;17(2):255-63. doi: 10.1517/14656566.2016.1133590. Epub 2016 Jan 14. Review.

PMID:
26679057
50.

Plasticity of brain wave network interactions and evolution across physiologic states.

Liu KK, Bartsch RP, Lin A, Mantegna RN, Ivanov PCh.

Front Neural Circuits. 2015 Oct 26;9:62. doi: 10.3389/fncir.2015.00062. eCollection 2015.

Supplemental Content

Loading ...
Support Center